Report

img

Lung Cancer Therapeutics Market 2025-2029

Snapshot
Table Of Contents
Methodology

Lung Cancer Therapeutics Market Outlook (2025–2029)

The global lung cancer therapeutics market is projected to grow by USD 12.39 billion during the forecast period, registering a CAGR of 8.4% from 2024 to 2029.

Market Overview

This growth is primarily fueled by the rising incidence of lung cancer and the rapid advancement of precision medicine. Precision therapies, especially immunotherapies, are transforming treatment approaches by leveraging genetic information to target tumors more effectively. Immunotherapy, in particular, enhances the body's immune response to combat cancer cells and is increasingly favored for its improved efficacy.

Pharmaceutical leaders like AbbVie Inc., with products such as Teliso-V, are at the forefront of innovation. Meanwhile, the emergence of regenerative therapies and targeted treatments is creating new avenues for managing the disease. Despite the continued relevance of chemotherapy, its side effects and limitations are accelerating the shift toward less toxic, more effective solutions.

Key Market Drivers

  • Rising Adoption of Immunomodulators: The market is propelled by the growing approvals of PD-1 and PD-L1 inhibitors, showing improved survival and response rates in NSCLC and SCLC cases.
  • High Disease Burden: Lung cancer remains a leading cause of cancer-related deaths globally, accounting for ~13% of all cancer fatalities.
  • Technological Advancements: Progress in nanomedicine, biomarkers, and diagnostic tools are enhancing early detection and personalized treatment.
  • R&D Investments: Companies are investing heavily in the development of small molecules, gene therapies, and monoclonal antibodies.

Emerging Trends

  • Regenerative Medicine: Research into gene-based regenerative therapies aims to address the genetic roots of lung cancer, particularly in NSCLC.
  • Precision Medicine Expansion: Growing focus on genetic profiling and individualized therapies.
  • Nanomedicine: Use of nanotechnology for precise drug delivery is gaining momentum.

Key Challenges

  • Side Effects of Current Therapies: Toxicity and adverse reactions from chemotherapy, immunotherapy, and radiation remain major concerns.
  • Patient Preference for Traditional Options: Surgery and radiation are often preferred for early-stage treatment due to cost and familiarity.
  • Awareness and Early Diagnosis: Lack of widespread awareness and access to advanced diagnostics hampers timely intervention.

Major Companies:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Astellas Pharma Inc.
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA, and others.

These companies are categorized based on market presence into dominant, strong, and emerging players and assessed for both qualitative and quantitative performance.

Table of Content

1 Executive Summary

1.1 Market overview

  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Therapy
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

2.2 Criticality of inputs and Factors of differentiation

  • Overview on criticality of inputs and factors of differentiation

2.3 Factors of disruption

  • Overview on factors of disruption

2.4 Impact of drivers and challenges

  • Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

3.1 Market ecosystem

  • Parent Market
  • Data Table on - Parent Market

3.2 Market characteristics

  • Market characteristics analysis

3.3 Value chain analysis

  • Value chain analysis

4 Market Sizing

4.1 Market definition

  • Offerings of companies included in the market definition

4.2 Market segment analysis

  • Market segments

4.3 Market size 2024

4.4 Market outlook: Forecast for 2024-2029

  • Chart on Global - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Global - Market size and forecast 2024-2029 ($ billion)
  • Chart on Global Market: Year-over-year growth 2024-2029 (%)
  • Data Table on Global Market: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

5.1 Global Lung Cancer Therapeutics Market 2019 - 2023

  • Historic Market Size - Data Table on Global Lung Cancer Therapeutics Market 2019 - 2023 ($ billion)

5.2 Therapy segment analysis 2019 - 2023

  • Historic Market Size - Therapy Segment 2019 - 2023 ($ billion)

5.3 Type segment analysis 2019 - 2023

  • Historic Market Size - Type Segment 2019 - 2023 ($ billion)

5.4 End-user segment analysis 2019 - 2023

  • Historic Market Size - End-user Segment 2019 - 2023 ($ billion)

5.5 Geography segment analysis 2019 - 2023

  • Historic Market Size - Geography Segment 2019 - 2023 ($ billion)

5.6 Country segment analysis 2019 - 2023

  • Historic Market Size - Country Segment 2019 - 2023 ($ billion)

6 Qualitative Analysis

6.1 AI Impact on Global Lung Cancer Therapeutics Market

7 Five Forces Analysis

7.1 Five forces summary

  • Five forces analysis - Comparison between 2024 and 2029

7.2 Bargaining power of buyers

  • Bargaining power of buyers - Impact of key factors 2024 and 2029

7.3 Bargaining power of suppliers

  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029

7.4 Threat of new entrants

  • Threat of new entrants - Impact of key factors in 2024 and 2029

7.5 Threat of substitutes

  • Threat of substitutes - Impact of key factors in 2024 and 2029

7.6 Threat of rivalry

  • Threat of rivalry - Impact of key factors in 2024 and 2029

7.7 Market condition

  • Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by Therapy

8.1 Market segments

  • Chart on Therapy - Market share 2024-2029 (%)
  • Data Table on Therapy - Market share 2024-2029 (%)

8.2 Comparison by Therapy

  • Chart on Comparison by Therapy
  • Data Table on Comparison by Therapy

8.3 Targeted therapy - Market size and forecast 2024-2029

  • Chart on Targeted therapy - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Targeted therapy - Market size and forecast 2024-2029 ($ billion)
  • Chart on Targeted therapy - Year-over-year growth 2024-2029 (%)
  • Data Table on Targeted therapy - Year-over-year growth 2024-2029 (%)

8.4 Immunotherapy - Market size and forecast 2024-2029

  • Chart on Immunotherapy - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Immunotherapy - Market size and forecast 2024-2029 ($ billion)
  • Chart on Immunotherapy - Year-over-year growth 2024-2029 (%)
  • Data Table on Immunotherapy - Year-over-year growth 2024-2029 (%)

8.5 Chemotherapy - Market size and forecast 2024-2029

  • Chart on Chemotherapy - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Chemotherapy - Market size and forecast 2024-2029 ($ billion)
  • Chart on Chemotherapy - Year-over-year growth 2024-2029 (%)
  • Data Table on Chemotherapy - Year-over-year growth 2024-2029 (%)

8.6 Market opportunity by Therapy

  • Market opportunity by Therapy ($ billion)
  • Data Table on Market opportunity by Therapy ($ billion)

9 Market Segmentation by Type

9.1 Market segments

  • Chart on Type - Market share 2024-2029 (%)
  • Data Table on Type - Market share 2024-2029 (%)

9.2 Comparison by Type

  • Chart on Comparison by Type
  • Data Table on Comparison by Type

9.3 NSCLC - Market size and forecast 2024-2029

  • Chart on NSCLC - Market size and forecast 2024-2029 ($ billion)
  • Data Table on NSCLC - Market size and forecast 2024-2029 ($ billion)
  • Chart on NSCLC - Year-over-year growth 2024-2029 (%)
  • Data Table on NSCLC - Year-over-year growth 2024-2029 (%)

9.4 SCLC - Market size and forecast 2024-2029

  • Chart on SCLC - Market size and forecast 2024-2029 ($ billion)
  • Data Table on SCLC - Market size and forecast 2024-2029 ($ billion)
  • Chart on SCLC - Year-over-year growth 2024-2029 (%)
  • Data Table on SCLC - Year-over-year growth 2024-2029 (%)

9.5 Market opportunity by Type

  • Market opportunity by Type ($ billion)
  • Data Table on Market opportunity by Type ($ billion)

10 Market Segmentation by End-user

10.1 Market segments

  • Chart on End-user - Market share 2024-2029 (%)
  • Data Table on End-user - Market share 2024-2029 (%)

10.2 Comparison by End-user

  • Chart on Comparison by End-user
  • Data Table on Comparison by End-user

10.3 Hospitals and specialist clinics - Market size and forecast 2024-2029

  • Chart on Hospitals and specialist clinics - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Hospitals and specialist clinics - Market size and forecast 2024-2029 ($ billion)
  • Chart on Hospitals and specialist clinics - Year-over-year growth 2024-2029 (%)
  • Data Table on Hospitals and specialist clinics - Year-over-year growth 2024-2029 (%)

10.4 Research institutions and academic centers - Market size and forecast 2024-2029

  • Chart on Research institutions and academic centers - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Research institutions and academic centers - Market size and forecast 2024-2029 ($ billion)
  • Chart on Research institutions and academic centers - Year-over-year growth 2024-2029 (%)
  • Data Table on Research institutions and academic centers - Year-over-year growth 2024-2029 (%)

10.5 Other - Market size and forecast 2024-2029

  • Chart on Other - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Other - Market size and forecast 2024-2029 ($ billion)
  • Chart on Other - Year-over-year growth 2024-2029 (%)
  • Data Table on Other - Year-over-year growth 2024-2029 (%)

10.6 Market opportunity by End-user

  • Market opportunity by End-user ($ billion)
  • Data Table on Market opportunity by End-user ($ billion)

11 Customer Landscape

11.1 Customer landscape overview

  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

12.1 Geographic segmentation

  • Chart on Market share by geography 2024-2029 (%)
  • Data Table on Market share by geography 2024-2029 (%)

12.2 Geographic comparison

  • Chart on Geographic comparison
  • Data Table on Geographic comparison

12.3 North America - Market size and forecast 2024-2029

  • Chart on North America - Market size and forecast 2024-2029 ($ billion)
  • Data Table on North America - Market size and forecast 2024-2029 ($ billion)
  • Chart on North America - Year-over-year growth 2024-2029 (%)
  • Data Table on North America - Year-over-year growth 2024-2029 (%)

12.4 Europe - Market size and forecast 2024-2029

  • Chart on Europe - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
  • Chart on Europe - Year-over-year growth 2024-2029 (%)
  • Data Table on Europe - Year-over-year growth 2024-2029 (%)

12.5 Asia - Market size and forecast 2024-2029

  • Chart on Asia - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
  • Chart on Asia - Year-over-year growth 2024-2029 (%)
  • Data Table on Asia - Year-over-year growth 2024-2029 (%)

12.6 Rest of World (ROW) - Market size and forecast 2024-2029

  • Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
  • Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)

12.7 US - Market size and forecast 2024-2029

  • Chart on US - Market size and forecast 2024-2029 ($ billion)
  • Data Table on US - Market size and forecast 2024-2029 ($ billion)
  • Chart on US - Year-over-year growth 2024-2029 (%)
  • Data Table on US - Year-over-year growth 2024-2029 (%)

12.8 UK - Market size and forecast 2024-2029

  • Chart on UK - Market size and forecast 2024-2029 ($ billion)
  • Data Table on UK - Market size and forecast 2024-2029 ($ billion)
  • Chart on UK - Year-over-year growth 2024-2029 (%)
  • Data Table on UK - Year-over-year growth 2024-2029 (%)

12.9 Canada - Market size and forecast 2024-2029

  • Chart on Canada - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
  • Chart on Canada - Year-over-year growth 2024-2029 (%)
  • Data Table on Canada - Year-over-year growth 2024-2029 (%)

12.10 China - Market size and forecast 2024-2029

  • Chart on China - Market size and forecast 2024-2029 ($ billion)
  • Data Table on China - Market size and forecast 2024-2029 ($ billion)
  • Chart on China - Year-over-year growth 2024-2029 (%)
  • Data Table on China - Year-over-year growth 2024-2029 (%)

12.11 Japan - Market size and forecast 2024-2029

  • Chart on Japan - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
  • Chart on Japan - Year-over-year growth 2024-2029 (%)
  • Data Table on Japan - Year-over-year growth 2024-2029 (%)

12.12 France - Market size and forecast 2024-2029

  • Chart on France - Market size and forecast 2024-2029 ($ billion)
  • Data Table on France - Market size and forecast 2024-2029 ($ billion)
  • Chart on France - Year-over-year growth 2024-2029 (%)
  • Data Table on France - Year-over-year growth 2024-2029 (%)

12.13 Germany - Market size and forecast 2024-2029

  • Chart on Germany - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
  • Chart on Germany - Year-over-year growth 2024-2029 (%)
  • Data Table on Germany - Year-over-year growth 2024-2029 (%)

12.14 India - Market size and forecast 2024-2029

  • Chart on India - Market size and forecast 2024-2029 ($ billion)
  • Data Table on India - Market size and forecast 2024-2029 ($ billion)
  • Chart on India - Year-over-year growth 2024-2029 (%)
  • Data Table on India - Year-over-year growth 2024-2029 (%)

12.15 Spain - Market size and forecast 2024-2029

  • Chart on Spain - Market size and forecast 2024-2029 ($ billion)
  • Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
  • Chart on Spain - Year-over-year growth 2024-2029 (%)
  • Data Table on Spain - Year-over-year growth 2024-2029 (%)

12.16 South Korea - Market size and forecast 2024-2029

  • Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
  • Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
  • Chart on South Korea - Year-over-year growth 2024-2029 (%)
  • Data Table on South Korea - Year-over-year growth 2024-2029 (%)

12.17 Market opportunity by geography

  • Market opportunity by geography ($ billion)
  • Data Tables on Market opportunity by geography ($ billion)

13 Drivers, Challenges, and Opportunity/Restraints

13.1 Market drivers

13.2 Market challenges

13.3 Impact of drivers and challenges

  • Impact of drivers and challenges in 2024 and 2029

13.4 Market opportunities/restraints

14 Competitive Landscape

14.1 Overview

14.2 Competitive Landscape

  • Overview on criticality of inputs and factors of differentiation

14.3 Landscape disruption

  • Overview on factors of disruption

14.4 Industry risks

  • Impact of key risks on business

15 Competitive Analysis

15.1 Companies profiled

  • Companies covered

15.2 Company ranking index

  • Company ranking index

15.3 Market positioning of companies

  • Matrix on companies position and classification

15.4 AbbVie Inc.

  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT

15.5 Amgen Inc.

  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key news
  • Amgen Inc. - Key offerings
  • SWOT

15.6 Astellas Pharma Inc.

  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key offerings
  • SWOT

15.7 AstraZeneca Plc

  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT

15.8 Boehringer Ingelheim International GmbH

  • Boehringer Ingelheim International GmbH - Overview
  • Boehringer Ingelheim International GmbH - Product / Service
  • Boehringer Ingelheim International GmbH - Key news
  • Boehringer Ingelheim International GmbH - Key offerings
  • SWOT

15.9 Bristol Myers Squibb Co.

  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT

15.10 Daiichi Sankyo Co. Ltd.

  • Daiichi Sankyo Co. Ltd. - Overview
  • Daiichi Sankyo Co. Ltd. - Product / Service
  • Daiichi Sankyo Co. Ltd. - Key offerings
  • SWOT

15.11 Eli Lilly and Co.

  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT

15.12 F. Hoffmann La Roche Ltd.

  • Hoffmann La Roche Ltd. - Overview
  • Hoffmann La Roche Ltd. - Business segments
  • Hoffmann La Roche Ltd. - Key news
  • Hoffmann La Roche Ltd. - Key offerings
  • Hoffmann La Roche Ltd. - Segment focus
  • SWOT

15.13 GlaxoSmithKline Plc

  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT

15.14 Merck and Co. Inc.

  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT

15.15 Novartis AG

  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT

15.16 Pfizer Inc.

  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • SWOT

15.17 Sanofi SA

  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT

15.18 Takeda Pharmaceutical Co. Ltd.

  • Takeda Pharmaceutical Co. Ltd. - Overview
  • Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Takeda Pharmaceutical Co. Ltd. - Key news
  • Takeda Pharmaceutical Co. Ltd. - Key offerings
  • SWOT

Research Methodology

All our research reports employ a mixed-methods approach, leveraging both primary and secondary research techniques to develop a comprehensive and well-informed analysis. The methodology ensures a balanced perspective by combining data-driven insights with expert opinions.

1. Secondary Research

Secondary research formed the foundation of the study, offering a contextual understanding of the market landscape, historical trends, and existing data. This phase involved gathering and analyzing information from:

  • Industry reports and whitepapers (e.g., McKinsey, Deloitte, Statista)
  • Academic journals and case studies
  • Company reports, investor presentations, and press releases
  • Government databases and regulatory publications
  • Trade publications, industry blogs, and news articles

2. Primary Research

To validate and complement secondary findings, extensive primary research was conducted. This included both quantitative data collection and qualitative insights, particularly through expert consultations.

a. Expert Consultations (Qualitative Primary Research)

In-depth interviews were conducted with a wide range of industry stakeholders, including:

  • Industry experts and consultants
  • Senior executives and decision-makers
  • Product managers and supply chain professionals
  • Academic researchers and analysts

b. Surveys and Questionnaires (Quantitative Primary Research)

Structured surveys were distributed among:

  • End-users/consumers
  • Retailers and distributors
  • Business-to-business (B2B) buyers

3. Data Validation and Triangulation

Findings from secondary and primary sources were cross-validated through data triangulation to ensure accuracy, consistency, and reliability. This process involved comparing insights from different sources and reconciling discrepancies through expert feedback.

4. Analytical Tools and Frameworks

Various analytical models were applied to interpret the collected data:

  • SWOT Analysis for understanding strengths, weaknesses, opportunities, and threats
  • Porter’s Five Forces to assess market competitiveness
  • PESTLE Analysis to evaluate external macroeconomic influences
  • Forecasting Models using historical data trends and regression analysis

Conclusion

The combination of comprehensive secondary research and robust primary data collection—enhanced by expert consultations—ensured the development of a well-rounded and in-depth analysis. This approach enables strategic decision-making backed by both empirical evidence and industry expertise.

For detailed methodology for this particular report please write to us on info@syovi.com

Buy Report


  • $1999


  • $2999


  • $4999

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts